Itracoe 400 SR Tablet contains Itraconazole 400 mg, a broad-spectrum triazole antifungal agent used primarily for the treatment of various systemic and superficial fungal infections. Itraconazole exerts its antifungal activity by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the conversion of lanosterol to ergosterol, a key component of fungal cell membranes. Disruption of ergosterol synthesis results in increased membrane permeability and ultimately fungal cell death. Itracoe 400 SR is indicated for the treatment of infections such as aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and other dermatophytic infections. The sustained-release formulation ensures prolonged plasma concentrations, enhancing therapeutic efficacy and improving patient compliance by reducing dosing frequency. It is generally well tolerated, with common adverse effects including gastrointestinal disturbances, headache, and rash. Caution is advised in patients with hepatic impairment, and potential drug interactions should be carefully monitored due to itraconazole’s inhibition of cytochrome P450 enzymes. Itracoe 400 SR should be administered under medical supervision, with dosage and duration tailored to the specific infection and patient response. Regular monitoring of liver function and clinical status is recommended during therapy to ensure safety and effectiveness.